A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status), without sensitizing EGFR or ALK mutations.
Epistemonikos ID: 68aeac382d851e16821bf0033cd2ea5dcb43cc4a
First added on: May 15, 2024